BMC Medical Co., Ltd. (SHE:301367)
China · Delayed Price · Currency is CNY 77.27
-2.27 (-2.85%)
At close: Feb 13, 2026
BMC Medical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,048 | 842.24 | 1,119 | 1,413 | 661.08 | 560.25 |
Other Revenue | 1.24 | 1.24 | 3.01 | 2.62 | 1.42 | 0.22 |
| 1,050 | 843.48 | 1,122 | 1,415 | 662.5 | 560.48 | |
Revenue Growth (YoY) | 34.70% | -24.85% | -20.70% | 113.64% | 18.20% | 117.29% |
Cost of Revenue | 538.88 | 449.31 | 619.28 | 828.15 | 377.5 | 196.72 |
Gross Profit | 510.73 | 394.17 | 503.14 | 587.22 | 285 | 363.76 |
Selling, General & Admin | 204.09 | 172.58 | 142.35 | 131.68 | 95.52 | 85.04 |
Research & Development | 122.28 | 124.62 | 116.98 | 72.86 | 48.28 | 33.65 |
Other Operating Expenses | 4.55 | -2.76 | -23.5 | -19.3 | -9.51 | -13.81 |
Operating Expenses | 333.63 | 297.2 | 238.62 | 189.01 | 134.53 | 103.04 |
Operating Income | 177.1 | 96.98 | 264.51 | 398.2 | 150.47 | 260.72 |
Interest Expense | -5.08 | -2.85 | -1.36 | -0.46 | -0.2 | - |
Interest & Investment Income | 58.97 | 62.36 | 63.36 | 20.09 | 11.56 | 7.84 |
Currency Exchange Gain (Loss) | 4.51 | 4.51 | -0.4 | 11.98 | -3.67 | -2.96 |
Other Non Operating Income (Expenses) | -1.51 | -0.85 | 0.2 | -0.26 | -0.53 | -0.68 |
EBT Excluding Unusual Items | 233.99 | 160.14 | 326.31 | 429.55 | 157.64 | 264.92 |
Gain (Loss) on Sale of Investments | 11.41 | 10.44 | - | - | - | - |
Gain (Loss) on Sale of Assets | -0.04 | 0.19 | 0.48 | 0.02 | - | 0.05 |
Asset Writedown | -12.08 | -3.06 | -0.02 | - | -0.01 | -0 |
Other Unusual Items | 8.27 | 8.42 | 7.27 | 5.52 | 6.24 | - |
Pretax Income | 241.54 | 176.14 | 334.03 | 435.09 | 163.86 | 264.97 |
Income Tax Expense | 26.08 | 17.54 | 34.2 | 54.06 | 18.18 | 37.11 |
Earnings From Continuing Operations | 215.47 | 158.6 | 299.83 | 381.03 | 145.68 | 227.86 |
Minority Interest in Earnings | -5.2 | -3.22 | -2.49 | -0.74 | - | - |
Net Income | 210.27 | 155.38 | 297.34 | 380.3 | 145.68 | 227.86 |
Net Income to Common | 210.27 | 155.38 | 297.34 | 380.3 | 145.68 | 227.86 |
Net Income Growth | 38.35% | -47.74% | -21.81% | 161.05% | -36.07% | 487.23% |
Shares Outstanding (Basic) | 89 | 89 | 90 | 71 | 67 | 67 |
Shares Outstanding (Diluted) | 89 | 89 | 90 | 71 | 67 | 67 |
Shares Change (YoY) | -0.61% | -0.29% | 26.33% | 5.67% | -0.16% | 1559.19% |
EPS (Basic) | 2.37 | 1.74 | 3.32 | 5.36 | 2.17 | 3.39 |
EPS (Diluted) | 2.37 | 1.74 | 3.32 | 5.36 | 2.17 | 3.39 |
EPS Growth | 39.21% | -47.59% | -38.11% | 147.04% | -35.96% | -64.60% |
Free Cash Flow | 33.3 | 138.16 | 126.98 | 351.46 | 94.38 | 251.99 |
Free Cash Flow Per Share | 0.38 | 1.55 | 1.42 | 4.96 | 1.41 | 3.75 |
Dividend Per Share | 0.400 | 0.400 | 1.000 | 1.429 | - | 0.429 |
Dividend Growth | -60.00% | -60.00% | -30.00% | - | - | -85.00% |
Gross Margin | 48.66% | 46.73% | 44.83% | 41.49% | 43.02% | 64.90% |
Operating Margin | 16.87% | 11.50% | 23.57% | 28.13% | 22.71% | 46.52% |
Profit Margin | 20.03% | 18.42% | 26.49% | 26.87% | 21.99% | 40.65% |
Free Cash Flow Margin | 3.17% | 16.38% | 11.31% | 24.83% | 14.24% | 44.96% |
EBITDA | 190.06 | 108.64 | 274.46 | 403.85 | 155.09 | 262.59 |
EBITDA Margin | 18.11% | 12.88% | 24.45% | 28.53% | 23.41% | 46.85% |
D&A For EBITDA | 12.96 | 11.67 | 9.95 | 5.65 | 4.62 | 1.87 |
EBIT | 177.1 | 96.98 | 264.51 | 398.2 | 150.47 | 260.72 |
EBIT Margin | 16.87% | 11.50% | 23.57% | 28.13% | 22.71% | 46.52% |
Effective Tax Rate | 10.80% | 9.96% | 10.24% | 12.42% | 11.09% | 14.01% |
Revenue as Reported | 1,050 | 843.48 | 1,122 | 1,415 | 662.5 | - |
Advertising Expenses | - | 46.39 | 39.67 | 6.74 | 4.26 | 3.53 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.